Order Article Reprints

Signorelli C, Calegari MA, Anghelone A, Passardi A, Frassineti GL, Bittoni A, Lucchetti J, Angotti L, Di Giacomo E, Zurlo IV, et al. Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study. Current Oncology. 2024; 31(12):7793-7808. https://doi.org/10.3390/curroncol31120574

Signorelli, Carlo, Maria Alessandra Calegari, Annunziato Anghelone, Alessandro Passardi, Giovanni Luca Frassineti, Alessandro Bittoni, Jessica Lucchetti, Lorenzo Angotti, Emanuela Di Giacomo, Ina Valeria Zurlo, and et al. 2024. "Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study" Current Oncology 31, no. 12: 7793-7808. https://doi.org/10.3390/curroncol31120574

Signorelli, C., Calegari, M. A., Anghelone, A., Passardi, A., Frassineti, G. L., Bittoni, A., Lucchetti, J., Angotti, L., Di Giacomo, E., Zurlo, I. V., Morelli, C., Dell’Aquila, E., Artemi, A., Gemma, D., Corsi, D. C., Emiliani, A., Ribelli, M., Mazzuca, F., Arrivi, G., ... Basso, M. (2024). Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study. Current Oncology, 31(12), 7793-7808. https://doi.org/10.3390/curroncol31120574